A Randomized, Parallel-Group, Double-Blind, Placebo-Controlled, MultiCenter Study of Eculizumab for the Prevention of Delayed Graft Function after Kidney Transplantation in Adult Subjects at Increased Risk of Delayed Graft Function
A study for kidney transplant subjects using study drug eculizumab to prevent delayed graft function
Sponsor: Alexion Pharmaceuticals
Enrolling: Male and Female Patients
IRB Number: AAAN8450
U.S. Govt. ID: NCT02145182
Contact: Lloyd Ratner: 212-305-9691 / lr2182@columbia.edu
Additional Study Information: The purpose of this study is to determine if eculizumab is safe and could be used to prevent Delayed Graft Function (DGF) following kidney transplantation. DGF is an early complication of kidney transplantation. This condition occurs when the transplanted kidney does not recover instantly after transplantation and can take days to weeks before recovering fully.This study will be conducted in approximately 70 kidney transplant centers in about 8 countries around the world. About 15 subjects will be enrolled here at Columbia University Medical Center.
This study is closed
Investigator
Lloyd Ratner, MD, MPH, FACS
Do You Qualify?
Are you scheduled to receive a multi-organ transplant? Yes No
Do you currently have an active bacterial or other infection? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Lloyd Ratner
lr2182@columbia.edu
212-305-9691
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE